|
Showing 1 - 10 of
10 matches in All Departments
Comprehensive, condensed new edition covering the entire
specialties of Hematology/Oncology and Cellular Therapy (Volumes 1
and 2) Cancer Consult: Expertise for Medical Oncology/Hematology
and Cellular Therapy, Second Edition includes hundreds of
painstakingly developed multiple-choice and open-ended questions
covering the principles, uncertainties, and controversies of
medical oncology, neoplastic hematology, hematopoietic stem cell
transplant and cellular therapies including comprehensive chapters
on different aspect of cancer supportive care. This textbook also
contains mini-cases and questions dealing with the biology,
diagnosis, classification, staging, and multidisciplinary treatment
of cancers. This book also includes: Streamlined, engaging content
to make finding information easier and more beneficial to the
reader Up-to-date information on the very latest topics such as
molecular techniques, targeted therapies, immunotherapy, cellular
therapy, CAR T-cell therapy and translational cancer research
Concise and practical expert perspectives that reference key
studies and journals References to the latest NCCN and other
national guidelines With its powerful focus on pragmatic clinical
diagnostic, therapeutic and prognostic approaches, Cancer Consult:
Expertise for Medical Oncology/Hematology and Cellular Therapy,
Second Edition (Volumes 1 and 2) will help keep hematology,
oncology and cellular therapy practitioners up-to-date, bridging
the gaps between journal and reference literature, conferences, and
their existing knowledge base. It also offers clinicians, trainees,
and fellows an excellent opportunity to enhance their preparation
for the ABIM hematology and oncology fellowship and recertification
exams onboards.
Comprehensive, condensed new edition covering the entire
specialties of Hematology/Oncology and Cellular Therapy (Volumes 1
and 2) Cancer Consult: Expertise for Medical Oncology/Hematology
and Cellular Therapy, Second Edition includes hundreds of
painstakingly developed multiple-choice and open-ended questions
covering the principles, uncertainties, and controversies of
medical oncology, neoplastic hematology, hematopoietic stem cell
transplant and cellular therapies including comprehensive chapters
on different aspect of cancer supportive care. This textbook also
contains mini-cases and questions dealing with the biology,
diagnosis, classification, staging, and multidisciplinary treatment
of cancers. This book also includes: Streamlined, engaging content
to make finding information easier and more beneficial to the
reader Up-to-date information on the very latest topics such as
molecular techniques, targeted therapies, immunotherapy, cellular
therapy, CAR T-cell therapy and translational cancer research
Concise and practical expert perspectives that reference key
studies and journals References to the latest NCCN and other
national guidelines With its powerful focus on pragmatic clinical
diagnostic, therapeutic and prognostic approaches, Cancer Consult:
Expertise for Medical Oncology/Hematology and Cellular Therapy,
Second Edition (Volumes 1 and 2) will help keep hematology,
oncology and cellular therapy practitioners up-to-date, bridging
the gaps between journal and reference literature, conferences, and
their existing knowledge base. It also offers clinicians, trainees,
and fellows an excellent opportunity to enhance their preparation
for the ABIM hematology and oncology fellowship and recertification
exams onboards.
Ever since the discovery of blood types early in the last century,
transfusion medicine has evolved at a breakneck pace. This second
edition of Blood Banking and Transfusion Medicine is exactly what
you need to keep up. It combines scientific foundations with
today's most practical approaches to the specialty. From blood
collection and storage to testing and transfusing blood components,
and finally cellular engineering, you'll find coverage here that's
second to none. New advances in molecular genetics and the
scientific mechanisms underlying the field are also covered, with
an emphasis on the clinical implications for treatment. Whether
you're new to the field or an old pro, this book belongs in your
reference library. Integrates scientific foundations with clinical
relevance to more clearly explain the science and its application
to clinical practice. Highlights advances in the use of blood
products and new methods of disease treatment while providing the
most up-to-date information on these fast-moving topics Discusses
current clinical controversies, providing an arena for the
discussion of sensitive topics. Covers the constantly changing
approaches to stem cell transplantation and brings you the latest
information on this controversial topic.
Multiple myeloma is the second most prevalent hematological
malignancy, with over 55,000 new cases diagnosed each year. This
exciting new text, edited by lauded authorities on the topic,
stands as the only available reference to assemble, review, and
synthesizes the latest studies on translational therapies and
clearly explains the impact of molecular pathogenesis, biology, and
prognostic factors on the diagnosis, prognosis, and
individualization of treatment and the development of novel
therapeutic options for patients with myeloma. Moving from the
bench to the bedside to the forefront of therapeutic development,
this source: helps clinicians and researchers effectively deploy
therapeutic strategies into clinical practice reflects trends in
the use of agents which target both the tumor cell and its bone
marrow microenvironment to overcome resistance to conventional
therapies considers the critical role of the bone marrow
microenvironment in the regulation of growth, survival, and homing
of multiple myeloma discusses novel therapies in phase I and phase
II trials, focusing specifically on therapeutic options for
patients with newly diagnosed or relapsed/refractory multiple
myeloma addresses novel therapies for other plasma cell disorders,
and provides the framework for the design of next generation agents
and combination therapies covers the entire scope of translational
work in multiple myeloma, from advances in molecular pathogenesis,
to prognostic factors, immunotherapy, and new options for newly
diagnosed and relapsed multiple myeloma patients
Despite the advances in conventional, novel agent and high dose
chemotherapy multiple myeloma (MM) remains incurable. In order to
overcome resistance to current therapies and improve patient
outcome, novel biologically-based treatment approaches are being
developed. Current translational research in MM focusing on the
development of molecularly-based combination therapies has great
promise to achieve high frequency and durable responses in the
majority of patients. Two major advances are making this goal
possible. First, recent advances in genomics and proteomics in MM
have allowed for increased understanding of disease pathogenesis,
identified novel therapeutic targets, allowed for molecular
classification, and provided the scientific rationale for combining
targeted therapies to increase tumor cell cytotoxicity and abrogate
drug resistance. Second, there is now an increased understanding of
how adhesion of MM cells in bone marrow (BM) further impacts gene
expression in MM cells, as well as in BM stromal cells (BMSCs). As
a result of these advances in oncogenomics on the one hand and
increased understanding of the role of the BM in the pathogenesis
of MM on the other, a new treatment paradigm targeting the tumor
cell and its BM microenvironment to overcome drug resistance and
improve patient outcome has now been developed. Thalidomide,
lenalidomide, and Bortezomib are three agents which target the
tumor cell in its microenvironment in both laboratory and animal
models and which have rapidly translated from the bench to the
bedside. Ongoing efforts are using oncogenomics and cell signaling
studies to identify next generation of therapies in MM on the one
hand, and to inform the design of combination trials on the other.
This new paradigm for overcoming drug resistance and improving
patient outcome in MM has great promise not only to change the
natural history of MM, but also to serve as a model for targeted
therapeutics directed to improve outcome of patients with MM.
Despite the advances in conventional, novel agent and high dose
chemotherapy multiple myeloma (MM) remains incurable. In order to
overcome resistance to current therapies and improve patient
outcome, novel biologically-based treatment approaches are being
developed. Current translational research in MM focusing on the
development of molecularly-based combination therapies has great
promise to achieve high frequency and durable responses in the
majority of patients. Two major advances are making this goal
possible. First, recent advances in genomics and proteomics in MM
have allowed for increased understanding of disease pathogenesis,
identified novel therapeutic targets, allowed for molecular
classification, and provided the scientific rationale for combining
targeted therapies to increase tumor cell cytotoxicity and abrogate
drug resistance. Second, there is now an increased understanding of
how adhesion of MM cells in bone marrow (BM) further impacts gene
expression in MM cells, as well as in BM stromal cells (BMSCs). As
a result of these advances in oncogenomics on the one hand and
increased understanding of the role of the BM in the pathogenesis
of MM on the other, a new treatment paradigm targeting the tumor
cell and its BM microenvironment to overcome drug resistance and
improve patient outcome has now been developed. Thalidomide,
lenalidomide, and Bortezomib are three agents which target the
tumor cell in its microenvironment in both laboratory and animal
models and which have rapidly translated from the bench to the
bedside. Ongoing efforts are using oncogenomics and cell signaling
studies to identify next generation of therapies in MM on the one
hand, and to inform the design of combination trials on the other.
This new paradigm for overcoming drug resistance and improving
patient outcome in MM has great promise not only to change the
natural history of MM, but also to serve as a model for targeted
therapeutics directed to improve outcome of patients with MM.
Despite the advances in conventional, novel agent and high dose
chemotherapy multiple myeloma (MM) remains incurable. In order to
overcome resistance to current therapies and improve patient
outcome, novel biologically-based treatment approaches are being
developed. Current translational research in MM focusing on the
development of molecularly-based combination therapies has great
promise to achieve high frequency and durable responses in the
majority of patients. Two major advances are making this goal
possible. First, recent advances in genomics and proteomics in MM
have allowed for increased understanding of disease pathogenesis,
identified novel therapeutic targets, allowed for molecular
classification, and provided the scientific rationale for combining
targeted therapies to increase tumor cell cytotoxicity and abrogate
drug resistance. Second, there is now an increased understanding of
how adhesion of MM cells in bone marrow (BM) further impacts gene
expression in MM cells, as well as in BM stromal cells (BMSCs). As
a result of these advances in oncogenomics on the one hand and
increased understanding of the role of the BM in the pathogenesis
of MM on the other, a new treatment paradigm targeting the tumor
cell and its BM microenvironment to overcome drug resistance and
improve patient outcome has now been developed. Thalidomide,
lenalidomide, and Bortezomib are three agents which target the
tumor cell in its microenvironment in both laboratory and animal
models and which have rapidly translated from the bench to the
bedside. Ongoing efforts are using oncogenomics and cell signaling
studies to identify next generation of therapies in MM on the one
hand, and to inform the design of combination trials on the other.
This new paradigm for overcoming drug resistance and improving
patient outcome in MM has great promise not only to change the
natural history of MM, but also to serve as a model for targeted
therapeutics directed to improve outcome of patients with MM.
Despite the advances in conventional, novel agent and high dose
chemotherapy multiple myeloma (MM) remains incurable. In order to
overcome resistance to current therapies and improve patient
outcome, novel biologically-based treatment approaches are being
developed. Current translational research in MM focusing on the
development of molecularly-based combination therapies has great
promise to achieve high frequency and durable responses in the
majority of patients. Two major advances are making this goal
possible. First, recent advances in genomics and proteomics in MM
have allowed for increased understanding of disease pathogenesis,
identified novel therapeutic targets, allowed for molecular
classification, and provided the scientific rationale for combining
targeted therapies to increase tumor cell cytotoxicity and abrogate
drug resistance. Second, there is now an increased understanding of
how adhesion of MM cells in bone marrow (BM) further impacts gene
expression in MM cells, as well as in BM stromal cells (BMSCs). As
a result of these advances in oncogenomics on the one hand and
increased understanding of the role of the BM in the pathogenesis
of MM on the other, a new treatment paradigm targeting the tumor
cell and its BM microenvironment to overcome drug resistance and
improve patient outcome has now been developed. Thalidomide,
lenalidomide, and Bortezomib are three agents which target the
tumor cell in its microenvironment in both laboratory and animal
models and which have rapidly translated from the bench to the
bedside. Ongoing efforts are using oncogenomics and cell signaling
studies to identify next generation of therapies in MM on the one
hand, and to inform the design of combination trials on the other.
This new paradigm for overcoming drug resistance and improving
patient outcome in MM has great promise not only to change the
natural history of MM, but also to serve as a model for targeted
therapeutics directed to improve outcome of patients with MM.
This issue of Hematology/Oncology Clinics of North America, devoted
to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles
in this issue include: Monoclonal Gammopathy of Undetermined
Significance and Smoldering Multiple Myeloma; Diagnosis and Risk
Stratification in Myeloma; Treatment of Newly Diagnosed Transplant
Eligible Patients; Treatment of Newly Diagnosed Transplant
Ineligible Patients; Treatment of Relapsed/Refractory Myeloma;
Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based
Therapies; Allotransplantation in Myeloma; and Waldenstrom's
Macroglobulinemia.
Multiple Myeloma (MM) is the second most common type of blood
cancer, resulting from an overproduction of cancerous
infection-fighting white blood cells, known as plasma cells. Plasma
cells are a crucial part of the immune system responsible for the
production of antibodies. Bortezomib is a promising anticancer drug
targeting the proteasome. This proteasome inhibitor induces cell
stress and apoptosis in the cancer cells. While multiple mechanisms
are likely to be involved, proteasome inhibition may prevent the
degradation of pro-apoptotic factors, permitting activation of
programmed cell death in neoplastic cells dependent upon the
suppression of proapoptotic pathways. This monograph on bortezomib
is a valuable source of information for researchers and clinicians
from the fields of oncology and pharmacology, working either in
academia or the pharmaceutical industry.
|
You may like...
Gloria
Sam Smith
CD
R407
Discovery Miles 4 070
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|